Together with our previous studies showing the role of FB, C3, FI and FH in AP, and C1r and C1s in the classical pathway in cSCC progression [25,26,27,28,29,30], these results provide further evidence for the role of specific complement components as biomarkers and potential therapeutic targets in cSCC (Figure 6). This evidence concerns the gene C3 and skin squamous cell carcinoma.